Document text
Principal Investigator: Jia Fang
Organization: ROSWELL PARK CANCER INSTITUTE CORP
Fiscal Year: 2024
Award: $381,884
Funding agency: National Cancer Institute
Project Summary
Dissecting the Mechanism of SETDB1 and its K867 Monoubiquitination in Lung Cancer Progression
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related mortality worldwide
and associated with high mutation burdens. During the last decade, biomarker-driven targeted therapies have
achieved clear clinical benefits in patients with several oncogenic driver mutations such as EGFR, BRAF and
ALK. However, the treatments for tumors with the most prevalent KRAS mutations remain challenging despite
of recent breakthrough in targeting KRAS-G12C mutation. In KRAS mutant NSCLC, the constitutively activated
downstream signaling ultimately leads to transcription reprogramming to sustain tumor growth and progression.
This process is orchestrated by a cohort of crucial transcription factors, whose temporal and spatial expression
is associated with distinct epigenetic changes. Thus, dissecting epigenetic mechanisms in this process could
open new avenues for targeting strategies. SETDB1 is a principal methyltransferase catalyzing histone H3K9
methylation, a major repressive epigenetic modification. The focal amplification and upregulation of SETDB1
have been observed in a wide range of cancers including NSCLC, suggesting it has pro-oncogenic function.
However, the mechanisms of action of SETDB1 in NSCLC remain elusive. In preliminary study, we uncovered
that SETDB1 upregulation in lung adenocarcinoma (ADC) correlates with poorer prognosis and significantly
co-occurs with KRAS gene alternations. In NSCLC cells harboring oncogenic RAS, SETDB1 loss attenuates
migration and invasion, invadopodia formation and ECM degradation. These phenotypic changes correlate
with reactivation of transcription factors FOXA2 and CDX2 which function as key regulatory nodes to impede
metastatic progression of KRAS mutant lung ADC. More importantly, Setdb1 loss in tumor cells derived from
metastatic KrasG12D;p53fl/fl lung ADC abolished their spontaneous ability to metastasize from the subcutaneous
tumor to the lungs. These findings argue for a novel concept that SETDB1-mediated epigenetic mechanisms
are critical for oncogenic KRAS-induced transcription reprogramming during lung ADC progression. Moreover,
we have demonstrated that SETDB1 is monoubiquitinated at lysine-867 by the UBE2E family of E2 enzymes
independent of E3s and this monoubiquitination is essential for SETDB1-mediated H3K9 methylation and ERV
silencing. Accordingly, one objective of this proposal is to delineate SETDB1's pro-metastatic activity in KRAS
mutant lung ADC using various genetically engineered mouse models and xenograft models. Another objective
is to dissect the mechanisms of lysine-867 monoubiquitination in SETDB1's pro-metastatic activity in vivo and
in vitro. Our central hypothesis is that SETDB1 plays important roles in KRAS mutant lung ADC progression
through epigenetic mechanisms that require its monoubiquitination dependent enzymatic activity. This project
is significant because it will characterize SETDB1 as an actionable drug target in KRAS mutant lung cancer
and identify novel molecular interfaces for targeting. Our long-term goal is to develop better and more effective
therapeutic strategies by delineating epigenetic mechanisms in lung cancer.
Terms: <Alleles><Allelomorphs><Anti-Oncogenes><Antioncogenes><Attenuated><B-raf-1><BRAF><BRAF gene><Basal Transcription Factor><Basal transcription factor genes><Biochemical><C-K-RAS><CDX-3><CDX2><CDX2 gene><CDX3><Cancer Cause><Cancer Etiology><Cancer Suppressor Genes><Cancers><Caudal Type Homeobox Transcription Factor 2><Caudal-Type Homeo Box Transcription Factor 3><Caudal-Type Homeobox Protein 2><Caudal-Type Homeobox Transcription Factor 3><Cell Body><Cell Communication and Signaling><Cell Function><Cell Locomotion><Cell Migration><Cell Movement><Cell Physiology><Cell Process><Cell Signaling><Cell-Extracellular Matrix><Cells><Cellular Function><Cellular Migration><Cellular Motility><Cellular Physiology><Cellular Process><Clinical><Common Neoplasm><Common Tumor><Complex><Data><Development><Drug Targeting><EC 2.1.1><ECM><EGF Receptor><EGFR><ERBB Protein><ERVs><ESET><Emerogenes><Endogenous Retroviruses><Enzyme Gene><Enzymes><Epidermal Growth Factor Receptor><Epidermal Growth Factor Receptor Kinase><Epidermal Growth Factor Receptor Protein-Tyrosine Kinase><Epidermal Growth Factor-Urogastrone Receptors><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Extracellular Matrix><Family><GEM model><GEMM model><Gene Down-Regulation><Gene Inactivation><Gene Silencing><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Alteration><Genetic Change><Genetic defect><Genetically Engineered Mouse><Goals><HER1><HERVs><Heterochromatin><Histones><Homeobox Protein CDX-2><Human><Human Endogenous Retroviruses><In Vitro><Insulin Regulating Transcription Factor CDX3><Intracellular Communication and Signaling><Invaded><K-RAS2A><K-RAS2B><K-Ras><K-Ras 2A><K-Ras-2 Oncogene><KG1T><KIAA0067><KRAS><KRAS driven oncogenesis><KRAS oncogenesis><KRAS(G12D)><KRAS-driven tumorigenesis><KRAS-mediated tumorigenesis><KRAS2><KRAS2 gene><KRASG12D><Ki-RAS><L-Lysine><Link><Lung><Lung Adenocarcinoma><Lung Respiratory System><Lysine><Malignant><Malignant - descriptor><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Mediating><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methylation><Methyltransferase><Mice><Mice Mammals><Modeling><Modern Man><Modification><Molecular><Monoubiquitination><Murine><Mus><Mutation><NSCLC><NSCLC - Non-Small Cell Lung Cancer><Neoplasm Metastasis><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Onco-Suppressor Genes><Oncogene K-Ras><Oncogenes-Tumor Suppressors><Oncogenic><Pathway interactions><Patients><Phenotype><Play><Process><Prognosis><Proteins><Proteomics><Pulmonary Cancer><Pulmonary malignant Neoplasm><RAFB1><RASK2><Recessive Oncogenes><Refractory><Regulation><Repression><Role><SETDB1><SETDB1 gene><Secondary Neoplasm><Secondary Tumor><Signal Transduction><Signal Transduction Systems><Signaling><Subcellular Process><System><TGF-alpha Receptor><Therapeutic><Transcription Activation><Transcription Factor Proto-Oncogene><Transcription Repression><Transcription factor genes><Transcriptional Activation><Transcriptional Repression><Transforming Growth Factor alpha Receptor><Tumor Cell><Tumor Suppressing Genes><Tumor Suppressor Genes><Ubiquitilation><Ubiquitination><Ubiquitinoylation><Up-Regulation><Upregulation><Urogastrone Receptor><Xenograft Model><attenuate><attenuates><biological signal transduction><biomarker development><biomarker driven><c-erbB-1><c-erbB-1 Protein><cancer metastasis><cancer progression><cell motility><cohort><developmental><driver lesion><driver mutation><epigenetically><erbB-1><erbB-1 Proto-Oncogene Protein><erbBl><gain of function><gene repression><gene signatures><genetic signature><genetically engineered mouse model><genetically engineered murine model><genome mutation><histone modification><human disease><in vivo><innovate><innovation><innovative><insight><loss of function><lung cancer><lung cancer cell><malignancy><methylase><migration><molecular targeted therapeutics><molecular targeted therapies><molecular targeted treatment><mortality><mouse model><murine model><mutant><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oncogenic KRAS><oncosuppressor gene><pathway><proto-oncogene protein c-erbB-1><pulmonary><restraint><social role><subcutaneous><subdermal><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutically effective><transcription factor><transcriptional reprogramming><transcriptional silencing><transmethylase><tumor><tumor cell metastasis><tumor growth><tumor progression><ubiquination><ubiquitin conjugation><v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog><v-raf Murine Sarcoma Viral Oncogene Homolog B1><xenograft transplant model><xenotransplant model>